Moisture Matters in Lyophilized Drug Product - Using an alternate moisture-generation method may provide more accurate data for regulatory submissions. - BioPharm International

ADVERTISEMENT

Moisture Matters in Lyophilized Drug Product
Using an alternate moisture-generation method may provide more accurate data for regulatory submissions.


BioPharm International
Volume 25, Issue 10, pp. 64-67


Leu-Fen Lin, PhD
Lyophilization, or freeze-drying, is a process by which a drug formulation is first frozen and then the ice is removed by sublimation under a vacuum. For a lyophilized drug product, the residual moisture specification is a crucial component of the data package for regulatory filing. A defined acceptable range of water content also provides flexibility in the manufacturing process. Such data are usually generated by assessing product stability at various moisture levels.


Richard Bunnell, PhD
The moisture content of the product vial in stability studies is usually inferred from that determined for sister vials. Such an approach raises two concerns. First, the moisture content of the vial in the stability study potentially may not be identical to the reference sister vials due to vial-to-vial variability, and therefore, may be imprecise for resolving stability issues. Second, moisture levels in the product being analyzed are usually generated by sorption of water (via exposure or equilibration) onto a previously highly dried sample, whereas the moisture in an actual product results from incomplete desorption (during freeze-drying). Further data must be obtained to justify that each individual product stability is the same no matter which method is used to introduce moisture, due to the unique properties of each product being evaluated.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Publishes Guidance on ANDA Submissions
July 10, 2014
EMA Recommends 39 Drugs in First Half of 2014
July 10, 2014
Biotech Industry Forms International Council
July 10, 2014
Novartis Personalized Cell Therapy Receives FDA Breakthrough Therapy Designation
July 9, 2014
FDA Urged to Preserve Biosimilar Naming Conventions
July 2, 2014
Author Guidelines
Source: BioPharm International,
Click here